{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-072046","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.703031+00:00","generated_at":"2026-05-21T04:56:48.356800+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Akari Therapeutics Q1 net loss $3.7M, cash $2.6M; advances ADC pipeline","bullets":["Net loss from operations $3.7M in Q1 2025 vs $5.6M in Q1 2024; R&D spend down to $0.8M.","Cash $2.6M as of March 31, 2025; March 2025 offering netted $6.0M, $4.0M received in April.","Appointed Mark Kubik as Head of Business Development, Oncology to strengthen ADC expertise.","Expects to present preclinical data for PH1-payload ADC at a scientific conference in H2 2025.","Pipeline lead AKTX-101 (Trop2/PH1 ADC) advancing; out-licensing non-core assets for non-dilutive capital."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-072046","json":"https://secwatch.observer/filing/0000950170-25-072046.json","markdown":"https://secwatch.observer/filing/0000950170-25-072046.md","text":"https://secwatch.observer/filing/0000950170-25-072046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025072046/0000950170-25-072046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025072046/aktx-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:56:48.356800+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}